...
首页> 外文期刊>Frontiers in Pharmacology >Efficacy and Safety of Midazolam Oral Solution for Sedative Hypnosis and Anti-anxiety in Children: A Systematic Review and Meta-Analysis
【24h】

Efficacy and Safety of Midazolam Oral Solution for Sedative Hypnosis and Anti-anxiety in Children: A Systematic Review and Meta-Analysis

机译:咪达唑仑口服镇静催眠和儿童抗焦虑的疗效和安全性:系统审查和荟萃分析

获取原文
           

摘要

Background: Midazolam is recommended by health guidelines for sedation and hypnosis in children. Oral solution is a suitable dosage form for children. But there is no conclusive evidence for sedative-hypnosis and antianxiety effects by midazolam oral solution in children. Methods: Relevant studies were identified through searching PubMed, Embase, Cochrane Library, CINAHL, International Pharmaceuticals, four Chinese electronic databases, and relevant lists. Two reviewers independently selected trials, assessed trial quality, and extracted the data. Results: Eighty-nine randomized controlled trials (RCTs) comparing midazolam oral solution with placebo or blank ( n = 33), dexmedetomidine ( n = 15), ketamine ( n = 11), different midazolam doses ( n = 10), midazolam injection ( n = 8), chloral hydrate ( n = 7), diazepam ( n = 5), N _(2)O ( n = 5), triclofos ( n = 4), butorphanol ( n = 2), fentanyl ( n = 2), hydroxyzine ( n = 1), and thiopental ( n = 1) were identified. Meta-analysis showed no significant difference in the success rate and duration of sedation and hypnosis between midazolam oral and injectable solution ( P & 0.05). The success rate of sedation and hypnosis of midazolam was higher than that of ketamine [risk ratio (RR) = 1.32, 95% CI (1.07, 1.62), I ~(2) = 0%, P & 0.01]. No significant difference was found in the success rate of sedation and hypnosis, mask acceptance, and parental separation between midazolam oral solution and dexmedetomidine ( P & 0.05), and the result of one cohort study was consistent. The results of RCTs and a prospective cohort study showed that the incidence of adverse drug reactions (ADR) was 19.57% (189/966). Incidence of adverse reactions between dose groups of (0.25, 0.5] and (0.5, 1.0] mg/kg was similar [Pf (95% CI) = 0.10 (0.04, 0.24) and Pf (95% CI) = 0.09 (0.02, 0.39), respectively], higher than that of the dose group of (0, 0.25] mg/kg [Pf (95% CI) = 0.01 (0.00, 0.19)]. Conclusions: Available evidence suggests that midazolam oral solution is as good as midazolam injection and dexmedetomidine and is better than ketamine. Based on efficacy and safety results, an oral midazolam solution dose of 0.5–1 mg/kg is recommended for children.
机译:背景:Midazolam是由儿童镇静和催眠的健康指南推荐。口服溶液是儿童合适的剂型。但是,没有确凿的证据是沉重催眠和儿童中孢唑溶液的抗皱作用。方法:通过搜索Pubmed,Embase,Cochrane图书馆,Cinahl,国际制药,四个中文电子数据库和相关名单来确定相关研究。两位审稿人独立选择试验,评估试验质量,并提取数据。结果:80九次随机对照试验(RCTS)与安慰剂或坯料(n = 33),甲胺(n = 15),氯胺酮(n = 11),不同咪达唑仑剂,咪达唑仑注射(n = 8),氯水合物(n = 7),diazepam(n = 5),n _(2)o(n = 5),triclofos(n = 4),丁丙醇(n = 2),芬太尼(n = 2),鉴定羟基嗪(n = 1)和硫喷妥(n = 1)。 Midazolam口服和可注射溶液之间的成功率和沉积物的成功率和持续时间没有显着差异(P& 0.05)。咪达唑仑的镇静和催眠成功率高于氯胺酮[风险比(RR)= 1.32,95%CI(1.07,1.62),I〜(2)= 0%,P& 0.01]。在镇静剂和催眠,面膜验收和咪达唑仑溶液和右甲酰胺溶液(P> 0.05)之间的父母分离中没有显着差异(P> 0.05),并且一致的结果是一致的。 RCT和预期队列研究的结果表明,不良药物反应(ADR)的发病率为19.57%(189/966)。 (0.25,0.5]和(0.5,1)mg / kg的剂量基团之间的不良反应发生率[PF(95%CI)= 0.10(0.04,0.24)和PF(95%CI)= 0.09(0.02, 0.39)分别高于(0,0.25] Mg / kg [PF(95%CI)= 0.01(0.00,0.19)]的剂量组。结论:可用证据表明咪达唑仑口服溶液如同好作为咪达唑仑注射和右甲酰胺,比氯胺酮更好。基于疗效和安全结果,为儿童建议口服咪达唑仑溶液剂量为0.5-1mg / kg。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号